Related Experiment Videos
When and how to treat acute hepatitis C?
Anna Licata1, Danilo Di Bona, Filippo Schepis
1Cattedra di Gastroenterologia, Istituto di Clinica Medica I, University of Palermo, Piazza delle Cliniche, 2, 90127 Palermo, Italy.
Journal of Hepatology
|December 3, 2003
Summary
Interferon treatment significantly improves sustained virological response rates in acute hepatitis C. Delaying therapy does not impact outcomes, and a daily induction dose is recommended.
Area of Science:
- Hepatology
- Virology
- Clinical Trials
Background:
- The optimal treatment for acute hepatitis C remains debated due to limited controlled trial data.
- This study addresses the controversy surrounding acute hepatitis C management.
Purpose of the Study:
- To evaluate the efficacy of interferon therapy for acute hepatitis C through a meta-analysis.
- Assessing interferon's role in achieving sustained virological response in acute hepatitis C patients.
Main Methods:
- A meta-analysis of 12 controlled trials (414 patients) published between 1985 and 2002.
- Included studies compared interferon treatment against no treatment for acute hepatitis C.
- Sustained virological response (SVR) was the primary outcome measure.
Main Results:
- Interferon significantly increased SVR rates by 49% compared to no treatment.
- Higher interferon doses correlated with increased SVR rates.
- Therapy initiation delayed by 8-12 weeks did not negatively affect SVR.
Conclusions:
- Evidence supports recommending interferon for acute hepatitis C treatment.
- Treatment timing (early vs. delayed) does not appear to influence response rates.
- A daily interferon induction dose in the first month is suggested as the optimal regimen.